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Abstract
Background: The development of protective immunity against malaria is slow and to be maintained, it requires
exposure to multiple antigenic variants of malaria parasites and age-associated maturation of the immune system.
Evidence that the protective immunity is associated with different classes and subclasses of antibodies reveals the
importance of considering the quality of the response. In this study, we have evaluated the humoral immune
response against Plasmodium falciparum blood stages of individuals naturally exposed to malaria who live in
endemic areas of Brazil in order to assess the prevalence of different specific isotypes and their association with
different malaria clinical expressions.
Methods: Different isotypes against P. falciparum blood stages, IgG, IgG1, IgG2, IgG3, IgG4, IgM, IgE and IgA, were
determined by ELISA. The results were based on the analysis of different clinical expressions of malaria
(complicated, uncomplicated and asymptomatic) and factors related to prior malaria exposure such as age and
the number of previous clinical malaria attacks. The occurrence of the H131 polymorphism of the FcγIIA receptor
was also investigated in part of the studied population.
Results: The highest levels of IgG, IgG1, IgG2 and IgG3 antibodies were observed in individuals with
asymptomatic and uncomplicated malaria, while highest levels of IgG4, IgE and IgM antibodies were predominant
among individuals with complicated malaria. Individuals reporting more than five previous clinical malaria attacks
presented a predominance of IgG1, IgG2 and IgG3 antibodies, while IgM, IgA and IgE antibodies predominated
among individuals reporting five or less previous clinical malaria attacks. Among individuals with uncomplicated
and asymptomatic malaria, there was a predominance of high-avidity IgG, IgG1, IgG2 antibodies and low-avidity
IgG3 antibodies. The H131 polymorphism was found in 44.4% of the individuals, and the highest IgG2 levels were
observed among asymptomatic individuals with this allele, suggesting the protective role of IgG2 in this population.
Conclusion: Together, the results suggest a differential regulation in the anti-P. falciparum antibody pattern in
different clinical expressions of malaria and showed that even in unstable transmission areas, protective immunity
against malaria can be observed, when the appropriated antibodies are produced.
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Background
The acquisition of natural immunity to malaria is slow
and requires repeated parasite exposure to be maintained
[1]. This immunity reduces the risk of both severe and
mild malaria but does not suppress parasitaemia. The
defense mechanisms require cooperation among antibod-
ies (Ab) and cellular immune responses [2]. There is evi-
dence that (Ab)-dependent mechanisms play an
important role in the reduction of parasitaemia and can
diminish clinical symptoms in humans, as demonstrated
by the passive transfer of hyperimmune immunoglobulin
G (IgG) [3,4].
Cooperation between monocytes and Ab appears to be
crucial in acquired protective immunity [5]. The Ab pro-
duced in response to infection are of particular impor-
tance, since certain isotypes known as cytophilic Ab can
cooperate with monocytes via FcγRI and FcγRII receptors
in opsonization and phagocytosis or participate in both
antibody-dependent cellular inhibition (ADCI) as well as
antibody-dependent cellular cytotoxicity (ADCC) [6-8].
Protection against the blood stage of Plasmodium falci-
parum seems to depend on the proportion of specific
cytophilic Ab relative to the proportion of non-cytophilic
Ab [9]. The predominance of IgG1 and IgG3 cytophilic Ab
in endemic areas has been associated with either lower
parasitaemia [10] or a lower risk of malaria attack [11,12].
Otherwise, noncytophilic Ab, such as IgG4, may inhibit
effector mechanisms by competing with cytophilic Ab and
are considered nonprotective [7,13]. IgG2 is non-
cytophilic, but could be correlated with protection in indi-
viduals carrying a specific allelic variant of monocytes
FcγRIIA receptor that can bind IgG2 [14].
IgE levels and IgE anti-plasmodial Ab are elevated in
human and experimental malaria infections, but their role
in protection and/or pathogenesis is not well-established
in malaria [15-17]. In fact, a negative correlation between
the IgE level and placental parasitaemia [18,19] and levels
of haemoglobin and platelets [20] has been found. The
IgE level was higher in cerebral P. falciparum malaria than
in uncomplicated malaria [16,21], while among patients
with severe malaria, the increase in IgE levels was related
to the deepness of the coma [20]. Recent data showed
higher IgE functional activity in asymptomatic and
uncomplicated malaria patients than in severe or cerebral
malaria groups [22].
Contradictory results have been also found in relation to
IgM Ab. Even though there are indirect epidemiological
data suggesting that IgM Ab does not participate in protec-
tion [23,24], some evidence suggests a protective role in
cases such as: (a) mice with an X-linked recessive B-cell
deficiency do not produce IgM and are susceptible to Plas-
modium yoelii [24]; (b) the addition of monoclonal IgM
Ab to a malaria vaccine, raising its protective properties
[25]; (c) the IgM level, which correlated with a decrease of
the parasitaemia in individuals living in an area of hyper-
endemic malaria [26]. In terms of IgA Ab, no specific func-
tion in malaria has been ascribed to these antibodies to
date.
The gradual development of natural immunity to malaria
has been observed in areas where malaria transmission is
high and stable. The great majority of the studies on the
prevalence of different immunoglobulin isotypes and
their role in malaria infection has been conducted in such
areas, but little is known about areas with unstable
malaria, such as the Amazon Basin of Brazil. The main
objective of this work was to compare the humoral
immune response in three groups of Plasmodium-infected
subjects living in malaria endemic areas of Brazil: (a) sub-
jects with non-cerebral complicated malaria, (b) subjects
with uncomplicated malaria, and (c) asymptomatic sub-
jects – investigating the distribution of P. falciparum blood
stages-specific isotypic Ab IgG, IgG1, IgG2, IgG3, IgG4
IgM, IgE and IgA. The avidity of IgG subclasses, a parame-
ter of humoral immune response quality that has received
little attention in studies on malaria, was also evaluated in
this study.
Materials and methods
Study area, subjects and serum samples
Venous blood samples were collected from 233 residents
from two cities, Peixoto de Azevedo and Manaus, in the
Amazon Basin of Brazil. Peixoto de Azevedo is in the state
of Mato Grosso (PA/MT) and Manaus is the capital of the
state of Amazonas (MA/AM). The equatorial and humid
climate of both cities is characterized by a rainy season
from November to April and a dry season from May to
October. Malaria transmission is unstable, with an
increase at the end of the rainy season. Informed consent
was obtained individually from all participants before the
blood sample was taken. This study was approved by the
Committee of Ethics of the Faculty of Medicine of the Uni-
versity of São Paulo, of the Institute of Tropical Medicine
of São Paulo (IMT/SP) and of the Foundation of Tropical
Medicine of Amazonas (FMT/AM). A questionnaire con-
taining vital statistics and reports of the number of previ-
ous malaria attacks was available from all individuals.
At the time of blood collection, thick blood films and/or
QBC® (Quantitative Buffy Coat) were prepared according
to standard protocols for all subjects. Based on the clinical
expression of malaria, three groups were defined: (a) 70
subjects presenting non-cerebral complicated malaria (52
P. falciparum and 18 Plasmodium vivax) (CM group); (b)
148 subjects presenting uncomplicated malaria (92 P. fal-
ciparum, 32 P. vivax, 23 P. falciparum and P. vivax, and 1
Plasmodium malariae) (UM group), and (c) 15 subjects
Malaria Journal 2008, 7:186 http://www.malariajournal.com/content/7/1/186
Page 3 of 11
(page number not for citation purposes)
with Plasmodium infection, but without malaria symp-
toms (9 P. falciparum, 1 P. vivax, 4 P. falciparum and P.
vivax, and 1 P. malariae) (AS group). Non-cerebral compli-
cated malaria was defined as either severe anaemia and/or
high parasitaemia, hypoglycaemia < 40 mg/dL, serum cre-
atinine level > 1,5 mg/dL. Uncomplicated malaria was
characterized by a positive blood smear and fever without
other causes of infections and no manifestations of severe
malaria as described above. Ninety serum samples from
malaria-naïve blood donors were used as negative control
in the assays. Table 1 shows some characteristics of the
population.
Enzyme-linked immunosorbent assay (ELISA) for IgG 
subclasses and IgE Ab
IgG subclasses and IgE Ab were detected with ELISA using
a Zwittergent-extracted P. falciparum blood stages antigen
as described above [27]. Flat-bottom plastic microplates
(Polysorb, NUNC) were coated with a P. falciparum anti-
gen diluted to 5 μg/mL in phosphate buffered saline (PBS)
(50 μL/well) for 2 h at 37°C and subsequently for 18 h at
4°C in a moist chamber. Plates were saturated with 5%
skim milk in PBS-Tw20 (200 μL/well) for 1 h at 37°C.
Serum dilutions in 1% skim milk in PBS-Tw20 (serum
diluent) (50 μL/well) were incubated for 40 min at 37°C
in duplicate wells, 1:50 for IgG1, IgG2 and IgG3, 1:5 for
IgG4. For IgE detection, IgG Abs were first depleted by
treating them with a 1:20 serum dilution with a sheep
anti-human IgG (Rf-absorbent, Dade Behring) (1:1). The
biotinylated sheep anti-human IgE antibody (Sigma
Chem. Co.) was diluted to 1:500 in serum diluent (50 μL/
well) and biotinylated mouse monoclonal Ab specific to
each IgG isotype were used at the following dilutions in
serum diluent (50 μL/well): anti-IgG1 (clone 8c/6-39;
Sigma Chem. Co.), 1:1,000; anti-IgG2 (clone HP 6014;
Sigma Chem. Co.), 1:500; anti-IgG3 (clone HP 6050;
Sigma Chem. Co.), 1:500; anti-IgG4 (clone HP 6025;
Sigma Chem. Co.), 1:500. The peroxidase-labeled strepta-
vidin was diluted to 1:1,000 (50 μL/well) in serum diluent
and incubated for 40 min at 37°C. The enzymatic reaction
was developed with hydrogen peroxide and tetramethyl-
benzidin (Sigma Chem. Co.) diluted in citrate-phosphate
buffer (H2O2-TMB) (50 μL/well) for 30 minutes at 37°C,
and the reaction was stopped with 25 μL/well of 2N
H2SO4. Spectrophotometric reading at 450 nm was per-
formed on a Titertek Multiskan (MKII)-MCC/340 spectro-
photometer.
The results were expressed as a reactivity index (RI) or con-
centration. The reactivity index (RI) was calculated as the
ratio of the serum sample optical density to the cut-off
optical density. Serum samples with an RI equal to or
greater than 1.0 were considered positive. The cut-off was
defined as the mean plus 2 SD of the optical density val-
ues obtained with 90 negative control sera. Standard
curves were drawn by testing in each microplate six serial
dilutions (5120, 1280, 320, 80, 20 and 5 ng/mL) of mye-
loma protein of any the four IgG subclasses (Sigma Chem.
Co.) or IgE myeloma. Coating was done as described
above with 50 μL/well of a mixture (1:1) of one κ and one
λ myeloma protein of each isotype. Concentrations of
antigen-bound Ig isotypes were calculated from standard
curves using a four-parameter log-logit function, with the
aid of the ELISA programme developed by Plikyatis et al
[28]. Competition experiments with IgG1, IgG2, IgG3 and
IgG4 purified myeloma (Sigma Chem. Co.) were per-
formed to check the specificity of anti-human IgG sub-
classes and no cross-reaction was observed.
The avidity of anti-P. falciparum IgG and IgG subclasses
was assessed with an urea-elution based ELISA. Micro-
plates were coated and saturated as described above. After
serum samples were incubated, 8 M urea in PBS was
added (100 μL/well) for 5 min to one of the duplicates,
while PBS-Tw20 was added to the other duplicate. After
washing, the assay was completed as described above. The
avidity index (IA) was calculated as the ratio of the urea-
treated serum sample optical density to the non-treated
serum sample optical density, and multiplied by 100. All
values higher than 50% were ranked as high avidity and
values equal or lower than 50% were considered low avid-
ity.
ELISA for IgG, IgM and IgA Ab
Slight differences were noted among anti-P. falciparum
IgG, IgM and IgA Ab when analysed as described above.
Serum dilutions in serum diluent (50 μL/well) were incu-
bated for 40 min at 37°C in duplicate, 1:100 for IgG and
IgM, and 1:25 for IgA. The peroxidase-labeled sheep anti-
human IgG, IgM and IgA were diluted to 1:10,000,
Table 1: Characteristics of the studied population.
Characteristics Clinical expressions of malaria Total
CM (n = 70) UM (n = 148) AS (n = 15) n = 233
median age in years (25%–75%) 25.8 (17.0–40.0) 28.0 (22.0–37.0) 30.0 (25.8–39.5) 30.2
Sex (male/female %) 48.4/51.6 82.4/17.6 86.7/13.3
mean number of previous malaria attacks 3.7 ± 6.5 11.9 ± 8.9 14.8 ± 8.3 10.2
CM = complicated malaria, UM = uncomplicated malaria, AS = asymptomatic infection
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1:20,000 and 1:2,000, respectively, in serum diluent (50
μL/well) and incubated for 40 min at 37°C. The enzy-
matic reaction was developed with H2O2-TMB (50 μL/
well) for 30 minutes at 37°C, and the reaction was
stopped with 25 μL/well of 2N H2SO4. A spectrophoto-
metric reading at 450 nm was performed on a Titertek
Multiskan (MKII)-MCC/340 spectrophotometer.
Total human IgE and IgA measurement
The concentrations of total human IgE and IgA were deter-
mined in 66 serum samples from malaria endemic areas
using commercial nephelometry kits (Dade-Behring, Ger-
many).
Determination of FcγRIIA H/R131 polymorphism
FcγRIIA H/R131 polymorphism was determined in 126
DNA samples from the subjects by using an allele specific
restriction enzyme digestion method [29]. DNA extrac-
tion was performed as described by Snounou et al [30]
and modified by Ferreira et al [31]. First, the FcγRIIA-H/R
gene was amplified by PCR and the resulting product was
digested by the Bsh1236I (FnuDII) enzyme. The H131
allele contains a BstUI site in the 3' region and the R131
allele contains two BstUI sites in the 3' and 5' regions.
After BstUI digestion, the H/H131 genotype produces a
343 fragment, the R/R131 genotype produces a 322 frag-
ment and the H/R131 genotype produces one of each
fragment.
Statistical analysis
Analysis was carried out using SigmaStat software (Jandel
Scientific Corporation, CA). Antibody frequencies among
the three malaria groups were assessed by a χ2-test. Anti-
body levels in the three malaria groups were compared
using the non-parametric Kruskal-Wallis (KW) test and
the Mann-Whitney (MW) test when two groups were
compared. Correlations were assessed by Spearman rank
test (Sp), using real or logarithmically transformed values.
P values ≤ 0.05 were considered significant.
Results
Pattern of isotype response against P. falciparum blood 
stages considering different clinical expressions of malaria
IgG, IgG1, IgG2, IgG3, IgG4, IgM, IgA and IgE isotypes lev-
els were tested in P. falciparum blood-stage antigens of 233
Plasmodium-infected subjects presenting different clinical
expressions of malaria: complicated malaria (CM),
uncomplicated malaria (UM) and asymptomatic malaria
(AS). The results are presented on Table 2. Index of avidity
of IgG, IgG1, IgG2, IgG3 and IgG4 are also shown.
Levels of anti-P. falciparum IgG1, IgG2 and IgG3 Ab were
higher in the UM and AS groups than in the CM group
(KW, P < 0.0001). In contrast, levels of IgG4 were higher
in the CM group than in the UM and AS groups (P =
0.002). Also, IgE levels were higher in CM but without sig-
nificant differences (KW, P = 0.07). Levels of IgG, IgM and
IgA Ab did not differ among the groups (KW, P > 0.05).
Higher avidity indexes were observed for IgG, IgG1 and
IgG2 antibodies in the UM and AS groups compared to
the CM group (KW, P = 0.036; P < 0.0001; P = 0.014,
respectively) (Table 2).
Table 2: Results of the levels of different antibodies isotypes and their avidity against P. falciparum blood stages determined by ELISA 
in serum from 233 individuals infected with Plasmodium and classified according to the different clinical expressions of malaria: 
complicated malaria (CM), uncomplicated malaria (UM) and asymptomatic malaria (AS).
Levels of antibodies against P. falciparum blood stages Statistical
CM UM AS P
IgG1* 2.28 (0.80–10.37) 18.40 (7.23–44.8) 38.4 (3.95–71.8) < 0.0001
AI-IgG1+ 35.1 (24.7–64.7) 66.4 (44.4–86.7) 71.9 (62.2–84.6) < 0.0001
IgG2* 1.33 (0.67–3.00) 3.92 (2.26–17.1) 9.81 (2.25–89.8) < 0.0001
AI-IgG2+ 20.4 (16.8–68.6) 58.0 (37.5–76.6) 75.3 (62.0–92.6) 0.014
IgG3* 0.43 (0.19–0.91) 1.53 (0.72–3.74) 2.41 (0.53–9.47) < 0.0001
AI-IgG3+ 43.5 (22.0–53.6) 42.9 (27.1–66.5) 37.1 (29.4–53.3) 0.813
IgG4* 0.06 (0.00–0.14) 0.01 (0.00–0.04) 0.01 (0.00–0.03) 0.002
AI-IgG4+ 40.0 (2.8–77.8) 48.9 (36.0–59.1) - 0.471
IgG# 2.47 (0.73–5.44) 2.92 (1.36–4.39) 4.71 (1.59–6.58) 0.190
AI-IgG+ 48.4 (34.7–69.7) 63.3 (46.8–73.2) 63.4 (58.2–69.8) 0.036
IgE* 0.07 (0.03–0.16) 0.03 (0.00–0.11) 0.03 (0.01–0.21) 0.07
IgM# 1.08 (0.65–2.08) 0.86 (0.59–1.50) 1.04 (0.58–2.00) 0.106
IgA# 0.93 (0.56–2.09) 0.87 (0.60–1.88) - 0.661
*Levels expressed as concentration median (μg/mL)
# Levels expressed as the index of reactivity (IR) calculated as [sample optical density (OD)/cut-off OD]
+ AI = avidity index mean, calculated as (urea-treated sample OD/PBS sample OD)*100
P value for Kruskal Wallis non-parametric test
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The prevalence of IgG1, IgG2 and IgG3 Ab was signifi-
cantly higher in the UM and AS groups than in the CM
group (χ2 = 42.5%; P < 0.0001; χ2 = 12.7%; P = 0.002; χ2
= 10.1%; P = 0.006, respectively) (Table 3). The preva-
lence of IgG4, IgE, IgG, IgM and IgA Ab did not differ sig-
nificantly among the three groups (P > 0.05). High-avidity
IgG, IgG1, IgG2 and IgG4 Ab predominated in the UM
and AS groups, while low-avidity Ab predominated in the
CM group, although a significant difference was only
noted for IgG1 Ab (χ2 = 16.4; P = 0.0003). Low-avidity
IgG3 Ab predominated in the three groups, but with no
significant differences (P > 0.05) (Table 3).
With regards to the Plasmodium species, there was a signif-
icant difference in IgG1 Ab frequency when P. falciparum
(78.4%) was compared with P. vivax (62.7%) infected
patients (χ2 = 4.16; P = 0.04); and when P. vivax (62.7%)
was compared with P. falciparum and P. vivax (92.6%)
infected patients (χ2 = 6.55; P = 0.01). On the other hand,
no significant difference was observed for all other Ab
classes and subclasses studied (P > 0.05).
Different immunoglobulin isotypes can react with the
same epitopes but can influence the course of an infection
differently. In view of this fact, some of the interactions of
different isotypes against P. falciparum were compared in
the groups of subjects presenting different clinical expres-
sions of malaria. Interactions of IgG1, IgG2 and IgG3 were
higher among the UM and AS groups, while interactions
of IgG4 and IgE were higher in the CM group. Higher
IgG2/IgG4 and IgG/IgM ratios were observed in the UM
and AS groups (Table 4).
Association with variables indicative of prior malaria 
exposure
The influence of age and the number of previous clinical
malaria attacks on the levels of the isotypes specific for P.
falciparum blood-stage antigens was evaluated. Age was
positively correlated with IgG (Sp, r = 0.13; P = 0.033),
IgG1 (Sp, r = 0.17; P = 0.008) and IgG2 Ab (Sp, r = 0,16;
P = 0.008). The number of previous clinical malaria
attacks was positively correlated with IgG, IgG1 (Sp, r =
0.51; P = 0.00), IgG2 (Sp, r = 0.43; P = 0.00) and IgG3 (Sp,
r = 0.33; P = 0.00), and negatively correlated with IgG4
(Sp, r = -0.23; P = 0.001). Levels of IgG1, IgG2, IgG3 and
IgG were significantly higher in subjects reporting more
than five previous clinical malaria attacks than among
those reporting one to five previous clinical malaria
attacks or those undergoing their first malaria episode
(KW, P < 0.0001). Conversely, the levels of IgG4 and IgE
were significantly higher in subjects undergoing their first
malaria episode (KW, P = 0.0004). No significant differ-
ence was observed in the levels of IgM and IgA Ab (P >
0.05).
The mean avidity indexes (mAI) of the IgG1 Ab increased
significantly with the number of previous clinical malaria
attacks: above five previous clinical malaria attacks (mAI
= 71.7%), one to five previous clinical malaria attack (mAI
= 52.2%) and the first malaria episode (mAI = 22.9%)
(KW, P < 0.0001). The AI of IgG, IgG2, IgG3 and IgG4 Ab
were not statistically different (KW, P > 0.05).
Determination of total IgE and IgA
Total IgE and IgA levels were investigated in 66 serum
samples of the Plasmodium-infected subjects using a neph-
elometry assay. The median of the total IgE levels was
1,095 UI/mL, which is higher than normal human levels
(100 UI/mL); only four subjects had normal total IgE lev-
els. Of the 62 serum samples with high total IgE levels, 40
(64.5%) had anti-P. falciparum IgE Ab and 22 (35.5%) did
not (P = 0.002). The median of the total IgA levels was
2.00 g/L, while normal levels are between 0.7 and 2.0 g/L.
Three serum samples showed that total IgA levels were
Table 3: Frequency of antibodies against P. falciparum blood stages determined with ELISA in serum from 233 individuals infected with 
Plasmodium and classified according to the different clinical expressions of malaria: complicated malaria (CM), uncomplicated malaria 
(UM) and asymptomatic malaria (AS).
Frequency of individuals (%)
Isotype CM UM AS
total high/low avidity total high/low avidity total high/low avidity
IgG1 50.0 58.8/41.2 89.9 86.4/13.6 73.3 100.0/0
IgG2 24.3 47.1/52.9 47.3 85.5/14.5 60.0 100.0/0
IgG3 41.4 65.5/34.5 64.2 73.1//26.9 60.0 66.7/33.3
IgG4 18.0 55.6/44.4 16.5 77.3/22.7 6.7 100.0/0
IgG 71.4 81.4/18.6 79.1 93.8/6.2 73.3 100.0/0
IgE 39.1 - 37.6 - 35.7 -
IgM 58.6 - 39.9 - 53.3 -
IgA 46.2 - 40.0 - 60.0 -
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higher than normal, while four serum samples were
below normal levels.
Determination of FcγRIIA H/R131 polymorphism
Since the occurrence of FcγRIIA H/R131 polymorphism
grants IgG2 Ab a cytophilic function and results show
higher IgG2 levels in uncomplicated and asymptomatic
malaria than in complicated malaria, the distribution of
FcγRIIA H/R131 in the population was analysed. The
FcγRIIA H/R131 genotype was examined using genomic
DNA from 126 Plasmodium-infected subjects. Overall, the
H131 allele was found in 44.4% of the subjects; 15.1%
were H/H, 58.7% were H/R and 26.2% were R/R. IgG2 Ab
levels were higher in the asymptomatic subjects with the
H131 allele (78.6 mg/mL) than in those without it (38.1
mg/mL), but this difference was not significant. A signifi-
cant difference was observed in IgG2 levels when asymp-
tomatic subjects with the H131 allele were compared to
symptomatic subjects without the H131 allele (4.5 mg/
mL) (MW, P = 0.02) (Table 5).
Discussion
In this study it was investigated how IgG and its four sub-
classes, IgM, IgE and IgA isotypes, work against P. falci-
parum blood stages of individuals naturally exposed to
malaria living in different regions of Brazil. The results of
the different classes of immunoglobulins were analysed in
relation to the different clinical expressions of malaria:
complicated (CM), uncomplicated (UM) and asympto-
matic (AS) malaria. Factors related to prior malaria expo-
sure such as age and the number of previous clinical
malaria attacks were also analysed.
All the subjects were infected with P. falciparum and/or P.
vivax. It is likely that, due to the fact that a great number
of these subjects had suffered multiple malaria episodes
in the past and as a result of the cross-recognition of anti-
gens, the frequency of antibodies did not differ signifi-
cantly among the different infections; in any case, all
subjects were analysed.
The IgG, IgG1, IgG2 and IgG3 antibody levels and their
respective frequencies of positivity were higher in the UM
and AS groups than in the CM group. The isotype levels
were positively correlated with the number of past malaria
attacks and the IgG, IgG1 and IgG2 antibody levels were
positively correlated to age. These results are in line with
those of other authors who demonstrated that cytophilic
antibodies IgG1 and IgG3 were related to uncomplicated
malaria. More specifically, several studies showed that
Table 4: Comparison of the interactions of isotypes against P. falciparum blood stages levels of 233 Plasmodium-infected subjects 
presenting different clinical expression of malaria.
Clinical expression of malaria
Interaction Complicated Uncomplicated Asymptomatic (P)*
IgG1+IgG3/IgG2+IgG4 2,16 3,35 1,70 0,061
IgG1+IgG2+IgG3/IgG4 0,36 9,12 32,1 < 0,001
IgG1+IgG3/2 1,45 10,94 23,94 < 0,0001
IgE+IgG4 0,16 0,06 0,06 0,0100
IgG2/IgG4 12,2 154,1 482,7 < 0,0001
IgG3/IgG4 4,29 39,79 82,83 < 0,0001
IgE+IgG4/IgG2 0,106 0,008 0,01 < 0,0001
IgM/IgG 0,565 0,39 0,36 0,032
IgG/IgM 1,77 2,56 2,81 0,031
IgG1+IgG2+IgG3/IgM+IgE+IgG4 5,32 13,87 18,87 < 0,0001
*P values were determined by the non-parametric Kruskal Wallis test.
Table 5: IgG2 levels against P. falciparum blood stage extract detected with ELISA and the FcγRIIA H131 divided into two groups 
(individuals with or without malaria symptoms) genotype.
Individuals Allele IgG2 antibodies
FcγRIIA H131 [] Md N pos % pos
Symptomatic R/R (n = 29) 4.5 (2.5–12.9) 14 48.3
(n = 113) H/H or H/R (n = 84) 4.4 (2.6–18.5) 43 51.2
asymptomatic R/R (n = 4) 5.6 (1.5–23.6) 2 50.0
(n = 13) H/H or H/R (n = 9) 78.6 (4.9–94.2) 7 77.8
Md = median of concentration (μg/mL)
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specific IgG1 and IgG3 antibodies could protect against
malaria, while lgG4 antibodies probably do not protect
against the disease [5,11,12,32-36]. A recent study in
Sudan also found lower prevalence of IgG antibodies
against three P. falciparum merozoite surface protein
(MSP) MSP antigens, MSP1-19, MSP2A, and MSP2B in
individuals with severe malaria than in uncomplicated
[37]. A recent cohort study of children in Burkina Faso has
investigated different isotypes against four vaccine candi-
dates antigens, apical membrane antigen 1 (AMA1),
MSP1-19, MSP3, and glutamate-rich protein (GLURP).
They observed association among IgG, IgG3 and IgG4
against GLURP and a borderline association of IgG to
MSP3 with reduced risk of malaria [38].
There have been reports of asymptomatic malaria in these
Brazilian regions, suggesting that a certain degree of natu-
ral immunity can develop [39,40]. Considering that the
development of immunity depends on the degree of pre-
vious exposure to the disease, the positive correlation with
factors related to prior malaria exposure suggest that these
isotypes could play a role in protection against the dis-
ease; this idea is supported by the varying frequencies
detected among the different clinical expressions of the ill-
ness.
In spite of the fact that the IgG2 antibodies did not partic-
ipate in the mechanisms that caused opsonization,
phagocytosis and ADCI as they do not bind to the FcγR
receptors (principally, FcγRIIA), the results showed a pre-
dominance of IgG2 antibodies among individuals from
the UM group. For this, the R131H polymorphism in the
FcγRIIA receptor gene was investigated. FcγRIIa is a low-
affinity IgG receptor with an important role in neutraliz-
ing events of malaria parasites mediated by monocytes
[41]. Its ability of binding immunoglobulin subtypes is
influenced by a polymorphism within the gene. An amino
acid change at position 131 within the FcγRIIa molecule,
arginine (R131) or histidine (H131) is critical for the
binding of human IgG2 that binds efficiently to FcγIIa-
H131 but not to FcγRIIa-R131, although both FcγRIIa
allotypes interact with IgG1 and IgG3 [13]. Previous stud-
ies have indicated that FcγRIIa polymorphism has an
impact on the susceptibility/resistance for malaria,
although their results have been contradictory. In some
studies, the H/H131 genotype was significantly associated
with susceptibility to severe malarial disease [42,43] while
in other studies the H/H131 genotype was associated with
mild malaria [44] or the H131 alleles were mildly protec-
tive against high-density parasitaemia [45]. In relation to
FcγRIIa-R/R131 genotype, it has been associated with pro-
tection against high levels of P. falciparum parasitaemia
[45] and against malarial disease [43,46]. In contrast, it
was also associated with the development of severe
malaria [44]. This discrepancy likely reflects differences in
study design or in malaria exposure rates, as well as
genetic differences between the populations. FcγRIIa pol-
ymorphism plays an important role in other infections.
FcγRIIa H/H 131 has been associated to protection from
encapsulated bacterial infections, in which IgG2 is critical
in host defense [47]. The R/R131 genotype has been
found to be a risk factor for recurrent bacterial respiratory
infections [48,49].
In the present study, the H131 allele was found in 44.4%
of the subjects; 15.1% were H/H, 58.7% were H/R and
26.2% were R/R. The frequency of the H131 allele was
very similar to that observed in a population of Burkina
Faso (43%) [14], when high levels of IgG2 specific for P.
falciparum antigens were also associated to protection
against malaria. Here, the levels of IgG2 Ab were higher in
the asymptomatic subjects with the FcγRIIA H/R131 allele
(78.6 mg/mL) than in those without this allele (38.1 mg/
mL), but this difference was not significant. However, a
significant difference was found in the levels of IgG2 of
asymptomatic individuals with the FcγRIIA H/R131 allele
and the symptomatic individuals without allele H131
(4.5 mg/mL) (MW, P = 0.02). The high levels of IgG2 that
were found in AS individuals carrying the H131 polymor-
phism could suggest that IgG2 plays a role as a cytophilic
antibody among this population.
The IgG4 levels showed a negative correlation with the
number of previous malaria episodes. In addition, the fre-
quency of positivity and the IgG4 levels were higher
among subjects from the CM group. The absence of
malaria protection in IgG4 antibodies has been observed
by other authors [9,14]. IgG4 inhibits the action of
cytophilic antibodies lgG1 and lgG3 in vitro; these anti-
bodies are responsible for mediating the opsonization of
infected erythrocytes [5]. Aucan et al observed that the
positive correlation of IgG4 with the risk of infection was
stronger when IgG2 levels were low, suggesting that IgG4
could be neutralizing the cellular cytotoxicity mediated by
monocytes or other effector cells that depend on IgG2.
Therefore, IgG4 could block the protection provided by
IgG2 [14].
Another essential aspect of the humoral immune response
is the functional affinity or avidity of the antibodies; this
is the measurement of the force between the antigen and
the antibody and it can reflect the quality of the antibod-
ies involved in protection or in different phases of the ill-
ness. When studying the avidity of anti-P. falciparum
blood stages antibodies among populations from the
endemic area with stable transmission in Africa and
unstable transmission in the Brazilian Amazon Basin, Fer-
reira et al noted a predominance of high avidity antibod-
ies, particularly IgG1, in the clinically immune African
subjects [50]. Among patients from the Brazilian Amazon
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low avidity antibodies were found during the acute phase
of the disease; these were probably the result of the poly-
clonal activation of B cells. Two months following chem-
otherapy, the proportion of high avidity IgG antibodies
had increased significantly, though the concentration of
cytophilic antibodies had decreased. These authors postu-
lated that high-quality anti-P. falciparum antibodies could
be initially produced during the intra-erythrocytic growth
of the parasite, and that these antibodies react when para-
sitaemias are still low, with higher effectiveness against
the severity of the disease. In the current study, low avidity
antibodies of all the immunoglobulins predominated
among subjects from the CM group, which could reflect
the prevalence in this group of individuals with few previ-
ous malaria episodes. On the other hand, the predomi-
nance of low avidity antibodies could show that
uncontrolled infection is related to an expression of
immunodeficiency [50]. In general, IgG3 antibodies were
low avidity, independently of the clinical expression of
malaria. This could be explained by their short half-life
(~7–8 days) compared to the half-life of subclasses IgG1,
IgG2 and IgG4 (~23 days) [51,52] and it probably sug-
gests that these antibodies are the main subclass of anti-
bodies induced in response to new variants of
polymorphic antigens of the erythrocytic stage of P. falci-
parum [53].
High overall levels of IgE have been found in populations
exposed to malaria [17], a fact that was also observed in
94% of the individuals studied. However, there is some
controversy as to the role of specific IgE antibodies and
whether they serve to protect against the disease or to
worsen the illness. The following findings could support
the theory that specific IgE antibodies provide protection
against malaria: a) positive correlations between IgE levels
and age [18,19]; b) high concentration of IgE among indi-
viduals with severe non-comatose malaria in comparison
to comatose individuals [54]; c) the association of high
anti-P. falciparum IgE levels with a reduced risk of develop-
ing clinical malaria [55,56].
On the other hand, other evidence suggests that IgE could
play a role in the pathogenesis of malaria; for example: a)
there is an increase of the levels of IgE among individuals
suffering from severe malaria in comparison to uncompli-
cated malaria [17,57-59]; b) IgE deposits were found in
brain microvessels and on parasited erythrocytes from cer-
ebral malaria patients [19] and in placentas infected with
P. falciparum [20]. Immunocomplexes of IgE with antigen
or with IgG anti-IgE could induce the expression of Fcε
receptors in monocytes and the interaction with these
receptors leads to the cellular activation and liberation of
TNF [60,61]. Although TNF may protect against the para-
sites, local superproduction leads to tissue damage; in
addition, elevated levels in the blood are related to sick-
ness and death in cases of severe malaria [62,63]. Here,
higher levels of IgE were observed among subjects suffered
from complicated malaria, though the difference was not
significantly higher (P = 0.07) for specific IgE found in the
group of individuals with complicated malaria.
The frequencies of positivity and the levels of the IgM anti-
bodies were higher among the primo-infected individuals
than among those who claimed to have had previous
bouts of malaria, decreasing with each additional previ-
ous episode. Primo-infected individuals were expected to
have high IgM antibody levels, since IgM is the first class
of antibody produced as a primary humoral response.
This must also contribute to the predominance of IgM
among subjects with complicated forms of malaria, since
the majority of the primo-infected subjects were suffering
from such forms of the disease.
The frequency of positivity of IgA antibodies does not
have a correlation with the number of previous malaria
episodes, though the IgA levels decreased with each previ-
ous episode. These results were in line with previous
results when the predominance of IgA antibodies among
primo-infected subjects was observed Since IgA deficiency
has been observed among certain populations [64], total
IgA levels were also investigated in this population, but
these levels were normal.
Conclusion
The selection of the isotype and the antibody affinity mat-
uration of an antibody are the results of a process of dif-
ferentiating B cells that occurs in the germinative centers
of the lymph nodes of an immune individual. However,
functional affinity or avidity depends on the antigen and
on the selection of cell clones that produce antibodies
with better cynetics for binding to the epitope. The selec-
tion of isotypes is a complex phenomenon that depends
on several different mechanisms, many of which are still
not fully understood [65]. The gradual development of
protective immunity against malaria probably corre-
sponds to a progressive modification in the regulation of
the immune response and not to the slow development of
a response or to poorly immunogenic or highly polymor-
phic molecules, as was believed for some time. Acquiring
immunity would appear to be related to the ability to
develop antibodies that, when bound to the antigen, are
capable of activating cells by setting off defense mecha-
nisms, reducing the proportion of antibodies with the
same specificity and blocking cell activation [6]. Immu-
nity to malaria results from a strong humoral immune
response against multiple antigenic targets, as suggested
by the inverse association of the risk of malaria with the
breadth specificity for distinct merozoite antigens, AMA1,
MSP-2, and MSP-3 [66], so it would be of interest to inves-
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tigate further the roles of different isotypes against multi-
ple vaccine candidate antigens in different populations.
In conclusion, the work reported here suggests a differen-
tial regulation in the anti-P. falciparum antibody profile in
different clinical expressions of malaria. Interactions of
the antibodies IgG1, IgG2 and IgG3 were predominant
among individuals from the AS and UM groups, while
interactions between IgG4 and IgE prevailed among indi-
viduals from the CM group. The IgG2/IgG4 levels were
higher in the AS and UM groups. The IgE/IgG levels were
significantly higher among CM individuals than among
those without clinical complications, which may suggest
that the IgG and IgE antibodies reactive against the same
epitopes could play exactly opposing functions during the
infection. Therefore, the relationship between the anti-
bodies IgG/IgE, IgG1-IgG2-IgG3/IgG4, IgG2/IgG4 and
IgG4-IgE/IgG2 could reflect the balance between protec-
tion and pathogenesis in malaria.
These results show that even in populations from regions
with unstable malaria transmission, a certain degree of
naturally acquired immunity can develop when the right
antibodies are produced. Also, the findings can contribute
to a better understanding of the role of different isotypes
in immunity to malaria and may provide new insights
into the development of malaria control strategies, espe-
cially vaccination.
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